# CJC-1295 without DAC (Mod GRF 1-29)

> CJC-1295 without DAC, also called Modified GRF (1-29) or Mod GRF 1-29, is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH) with four amino acid substitutions, including D-alanine at position 2. Unlike CJC-1295 with DAC, it lacks the maleimide-bearing lysine extension. Peer-reviewed data specific to this peptide are limited, and it has no regulatory approval.

Canonical: https://peptideproperties.com/compounds/cjc-1295-no-dac/

## Identity

- **Class:** Growth Hormone Secretagogues & GHRH Analogs
- **Also known as:** Mod GRF 1-29, Modified GRF (1-29), Tetrasubstituted GRF(1-29)
- **Molecular formula:** C152H252N44O42
- **Molecular weight:** 3367.9 g/mol
- **Monoisotopic mass:** 3366.8969 Da
- **CAS number:** 863288-34-0
- **PubChem CID:** 56841945
- **InChIKey:** XOZMWINMZMMOBR-HRDSVTNWSA-N
- **Sequence notes:** Per the PubChem record (CID 56841945): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. Relative to human GRF(1-29)-NH2 (sermorelin), position 2 is D-alanine instead of L-alanine, Asn8 is replaced by Gln, Gly15 by Ala and Met27 by Leu; C-terminal amide.

## Key facts

- Class: synthetic growth hormone-releasing hormone (GHRH) analogue
- Length: 29 amino acids with a C-terminal amide
- Substitutions versus human GRF(1-29)-NH2: D-Ala2, Gln8, Ala15, Leu27
- Formula C152H252N44O42; molecular weight 3367.9 g/mol (PubChem CID 56841945)
- Lacks the maleimidopropionyl-lysine extension that defines CJC-1295 with DAC
- Not approved by the FDA for any indication
- Prohibited in sport as a GHRH analogue under WADA rules

## What Is CJC-1295 without DAC?

CJC-1295 without DAC is a synthetic analogue of the first 29 residues of human growth hormone-releasing hormone (GHRH), modified at four positions. It also appears in the literature and in chemical databases as Modified GRF (1-29), Mod GRF 1-29 and tetrasubstituted GRF(1-29).A 2026 narrative review groups it with other GHRH analogues, including sermorelin, tesamorelin and CJC-1295 with Drug Affinity Complex (DAC), among unregulated peptides marketed as "research compounds" that are intended to modulate the growth hormone and insulin-like growth factor 1 (GH-IGF-1) axis.[1]The name CJC-1295 was first attached to a tetrasubstituted form of human GRF(1-29) that also carries an added lysine bearing a maleimidopropionamide group.[2] The version without DAC is the modified 29-residue peptide on its own, which is why the two compounds share a name but differ in structure. Peer-reviewed studies that examine this peptide by itself are limited.

## Chemical Structure and Molecular Identity

CJC-1295 without DAC is a 29-residue peptide with a C-terminal amide, the molecular formula C152H252N44O42 and a molecular weight of 3367.9 g/mol (PubChem CID 56841945). Its sequence follows human GRF(1-29)-NH2, the peptide known as sermorelin, except at four positions.
### The four substitutions

- Position 2: D-alanine in place of L-alanine
- Position 8: glutamine in place of asparagine
- Position 15: alanine in place of glycine
- Position 27: leucine in place of methionineBecause methionine 27 is replaced by leucine, the molecule contains no sulfur, unlike sermorelin. PubChem lists the InChIKey XOZMWINMZMMOBR-HRDSVTNWSA-N and the CAS numbers 863288-34-0 and 446036-97-1.Some synonyms attached to this PubChem record refer to the DAC form, such as "CJC 1295 with DAC" and "DAC:GRF acetate", even though the computed structure contains no maleimide group. Names alone are therefore an unreliable way to tell the two compounds apart; the formula and molecular weight are more useful checks.

## What the Published Literature Covers

The peer-reviewed literature on CJC-1295 without DAC is small and consists mainly of reviews and forensic analyses rather than controlled studies of the peptide itself. None of the PubMed records reviewed for this page report a clinical trial of this compound.
### Reviews of GH-axis peptides
A 2026 review contrasts peer-reviewed pharmacokinetic, pharmacodynamic and clinical evidence with online self-administration practices, stratifying peptides into evidence tiers that range from regulatory-grade randomized trial data to a complete absence of human studies. Across the peptide class it covers, reported adverse effects include prolactin and cortisol elevations, appetite changes, dysglycemia, fluid retention, myalgia, arthralgia and injection-site reactions.[1]
### The original CJC-1295 work
The 2005 study that identified CJC-1295 examined the DAC form, not the peptide described here. In rats, that albumin-binding derivative produced a 4-fold larger growth hormone area under the curve over 2 hours than unmodified human GRF(1-29) and remained in plasma beyond 72 hours.[2] These results show what the DAC extension adds; they should not be read as data on the version without it.
### Forensic findings
Danish customs seizures analyzed by liquid chromatography-high resolution mass spectrometry contained analogues of modified GRF 1-29, as well as of GHRP-2, GHRP-6 and ipamorelin. In every case the modification was an extra glycine at the N-terminus, and the authors recommended updating analytical methods accordingly.[3]Because the CJC-1295 name is applied to two different molecules, researchers typically confirm identity through mass spectrometry and HPLC data on a certificate of analysis.

## Regulatory and Research Status

CJC-1295 without DAC is not approved by the US Food and Drug Administration for any indication. A 2026 review notes the absence of regulatory approval for physique- or performance-related uses and the uncertainty surrounding product composition in unregulated supply chains.[1]GHRH and its analogues are prohibited in sport under the World Anti-Doping Agency Prohibited List. Forensic work has identified modified GRF 1-29 analogues in seized doping material, describing them as substances that can be used for performance enhancement.[3]For laboratory work, the main open questions are basic ones: independent pharmacology of the peptide without DAC, its stability, and confirmation of identity, given that the name is used loosely and seized products have contained structurally altered variants.

## FAQ

**Is CJC-1295 without DAC the same as Mod GRF 1-29?**
Yes. CJC-1295 without DAC, Modified GRF (1-29), Mod GRF 1-29 and tetrasubstituted GRF(1-29) refer to the same 29-residue peptide. It follows the human GRF(1-29)-NH2 sequence with four substitutions: D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27. PubChem lists it under CID 56841945.

**How is CJC-1295 without DAC different from CJC-1295 with DAC?**
CJC-1295 with DAC carries an extra C-terminal lysine bearing a maleimidopropionyl group, which was designed to bind circulating albumin and extend plasma half-life. The version without DAC is the modified 29-residue peptide alone. The 2005 study that named CJC-1295 tested the DAC form, so its long-circulation findings do not apply to the version without DAC.

**What is the molecular weight of CJC-1295 without DAC?**
PubChem lists CJC-1295 without DAC (CID 56841945) with a molecular weight of 3367.9 g/mol and the molecular formula C152H252N44O42. The peptide has 29 amino acids and a C-terminal amide. By comparison, CJC-1295 with DAC is heavier, at 3647.2 g/mol, because of its added lysine and maleimide group.

**Is CJC-1295 without DAC FDA approved?**
No. CJC-1295 without DAC has no FDA approval for any indication. A 2026 review of GH-axis peptides describes it among unregulated compounds marketed as research chemicals and notes uncertainty about product composition in unregulated supply chains. GHRH analogues are also prohibited in sport under World Anti-Doping Agency rules.

**How is CJC-1295 without DAC different from sermorelin?**
Both are 29-residue, C-terminally amidated GHRH analogues. Sermorelin matches the native human GRF(1-29) sequence, while CJC-1295 without DAC replaces four residues: L-alanine 2 with D-alanine, asparagine 8 with glutamine, glycine 15 with alanine and methionine 27 with leucine. Sermorelin also has a longer published research history.

## References

1. Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in endocrinology 2026. PMID: 42395176
2. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID: 15817669
3. Gajda PM, Holm NB, Hoej LJ, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug testing and analysis 2019. PMID: 30136411